News | Prostate Cancer | May 12, 2016

Quality of Life Meets Cure for Prostate Cancer Treatment

Vessel-sparing radiation combined with a better understanding of prostate anatomy can decrease sexual dysfunction

MRI, prostate cancer, radiation therapy, vessel sparing, quality of life

Radiation dose is delivered by beams directed from many angles combined with implanted seeds (white spots). By integrating the two types of radiation, the highest dose is delivered only within the tumor. The external beams correct any irregularity from the seeds. Thanks to MRI planning, very little dose goes to critical adjacent structures. Image courtesy of University of Michigan Health System.

May 12, 2016 — The prostate is a tiny organ surrounded by critical structures. When radiation treatments deliver dose to any of these structures, it can sometimes lead to problems such as erectile dysfunction and bladder or rectal irritation.

“We always have to keep cure as our first priority, but quality of life is a major secondary concern for men with prostate cancer,” said Patrick W. McLaughlin, M.D., professor of radiation oncology at the University of Michigan Medical School.

“In the past cure came at a steep price in lost quality of life, but with modern refinements it is increasingly possible to meet the new standard of successful prostate cancer treatment: cure with quality of life.”

McLaughlin is the senior author of a paper published in The Lancet Oncology that looks at how magnetic resonance imaging (MRI) and a clear understanding of the functional anatomy (and its variations from patient to patient) can allow radiation oncologists to plan a course of treatment that spares these critical structures.

The team started by defining the critical functions and structures that run through or near the prostate. These include the nerves, vessels and sphincters that control bladder function, erectile function and rectal function.

“The benefit of the functional anatomy approach goes well beyond improving sexual function. It has improved urinary and rectal function as well,” McLaughlin said.

Both radiation oncologists and surgeons are conducting ongoing research to improve their understanding of the functional anatomy. This is critical for both disciplines as they work to eliminate cancer while preserving function.

“We argue that current rates of side effects and changes after treatment are not fixed, and that further potential improvements in function preservation are possible and likely by pursuing this vessel-sparing approach,” said co-author Jae Lee, M.D., Ph.D., a radiation oncology resident.

The study authors also found that MRI was a critical tool for accurately outlining the prostate anatomy and planning radiation therapy. They could easily and precisely see the borders of the prostate on MRI. Images from computed tomography (CT) are much less clear, and it’s common to overestimate the area that needs to be treated. With a clear outline of the prostate and other critical structures on MRI, radiation oncologists can precisely target treatment to the prostate while avoiding these critical erectile tissues. The technique is called vessel-sparing radiation.

Aggressive prostate cancer is often treated with a combination of implanted radiated seeds and external beam radiation. The combination is more effective than either method alone in treating aggressive cancers.

Of 49 patients treated with combination seeds plus external beam radiation with at least five years of follow-up, 92 percent reported they were still able to be sexually active.

“We found no difference in quality of life for men given aggressive treatment. If you define the functional structures and limit dose to them, you can achieve cure and excellent quality of life,” said co-author Daniel E. Spratt, M.D., chief of the genitourinary radiation oncology program at the University of Michigan.

Vessel-sparing radiation requires physicians train in MRI anatomy to recognize and identify key structures. McLaughlin has previously developed a tool that is available free online called Prostadoodle. It includes a section on defining the erectile vessels.

In addition, MRI could be helpful in guiding patients to the best treatment option based on their unique anatomy. Is the tumor outside of the prostate gland? That would suggest the need for radiation therapy after surgery, if surgery is chosen as primary treatment. Does the patient have a short urinary sphincter? While rare, these patients have a higher risk of incontinence with surgery.

“For patients who appear to have slow-growing, non-aggressive cancers, MRI can confirm there is no aggressive cancer present. For such patients, surveillance is an excellent choice,” McLaughlin says. “By avoiding treatment altogether when appropriate, all the side effects and quality of life impact from treatment is avoided.”

“On the other end of the spectrum, MRI may actually reveal more serious cancers not sampled by the biopsy. This can shift treatment to a more aggressive approach necessary to cure such cancers.”

McLaughlin sees patients at the Assarian Cancer Center at Providence Park in Novi and Providence Cancer center in Southfield, Mich., which is part of the University of Michigan’s Radiation Oncology Network. All the research was completed at the Providence affiliate.

For more information: www.thelancet.com/oncology

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...